Phase II Study of LM-24C5
A phase 2 trial of LM-24C5 in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.
Overview
Phase II Study of LM-24C5 is a phase 2 interventional study registered as NCT07387081 by LaNova Medicines Limited, with 130 participants planned, started 2025-12-15 and due to reach its primary completion in 2028-05-21. Interventions recorded: LM-24C5.
Similar pages
not linked directly; found by shared links- TrialA Study of LM-24C5 For Advanced Solid Tumors
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of LM-299 in Subjects Advanced Malignant Tumors
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of LM-350 in Subjects With Advanced Solid Tumours
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.